Search clinical trials for: Chronic Graft-versus-Host Disease

Total 381530 results

University of Seville

Not yet recruiting

Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD

Stem Cell Transplant Complications | Graft-versus-host-disease | Hematological Malignancy | Hematologic Cancer | Graft Versus Host Disease, Chronic

Spain
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

Graft-Versus-Host Disease | GVHD | Undefined

United States
St. Petersburg State Pavlov Medical University

Recruiting

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)

Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloid Leukemia, Acute

Russian Federation
University of Kansas Medical Center
In8bio Inc.

Recruiting

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Precancerous/Nonmalignant Condition
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Lymphoma | Leukemia | Graft Versus Host Disease

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

United States, Spain, Korea, Republic of, Australia, Austria, Canada, France, Germany, Israel, Italy, Netherlands, Russian Federation, United Kingdom
University of Nebraska
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Secondary Myelofibrosis

United States
University of Nebraska

Completed

Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

Graft-versus-host-disease (GVHD)

United States
Syndax Pharmaceuticals

Active, not recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201)

Chronic Graft-versus-host-disease

Korea, Republic of, United States, Spain, Taiwan, France, Singapore, Belgium, Germany, Italy, Canada, Israel, Australia, United Kingdom, Greece, Poland, Portugal
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)

Chronic Graft Versus Host Disease

United States, Australia, Austria, Canada, China, Croatia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan
Incyte Corporation

Approved for marketing

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Graft-versus-host Disease (GVHD)
Emory University
CURE Foundation

Completed

BMT Autologous MSCs for GvHD

Acute Graft Versus Host Disease | Chronic Graft Versus Host Disease | Graft Versus Host Disease

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Roswell Park Cancer Institute

Completed

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center
Millennium: The Takeda Oncology Company

Completed

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Myeloid Hematologic Malignancy | Lymphoid Hematologic Malignancy

United States
Incyte Corporation

Approved for marketing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Graft-versus-host Disease (GVHD)

United States
Incyte Corporation

Terminated

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Hematologic Malignancies

United States, Spain, France, Italy
Grupo Espanol de trasplantes hematopoyeticos y...

Active, not recruiting

Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)

Spain
Emory University

No longer available

Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
Baxalta now part of Shire

Terminated

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Lymphoma | Leukemia | Graft Versus Host Disease

United States, Australia
Karolinska Institutet
Region Stockholm

Terminated

Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease

Graft-Versus-Host Disease

Sweden
Jonsson Comprehensive Cancer Center

Withdrawn

Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Leukemia | Graft Versus Host Disease
National Cancer Institute (NCI)

Terminated

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Graft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host Disease

United States
Mesoblast, Inc.

No longer available

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

Graft vs Host Disease | Graft-Versus-Host Disease

United States, Canada
Mesoblast, Inc.

No longer available

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
Masonic Cancer Center, University of Minnesota

Withdrawn

Bone Marrow Transplantation in Treating Patients With Leukemia

Lymphoma | Leukemia | Graft Versus Host Disease

United States
Roswell Park Cancer Institute

Completed

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Pharmacyclics LLC.

Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Completed

Pomalidomide for Chronic Graft-versus-Host Disease

Graft vs Host Disease | Graft-Versus-Host Disease

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
University College, London

Unknown

Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers (ProT4)

Lymphoma | Leukemia | Myelodysplastic Syndrome | Myeloma | Graft Versus Host Disease

United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

Graft-Versus-Host Disease (GVHD) Acute on Chronic

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Experimental Bone Marrow Transplant Protocol

Myelodysplastic Syndromes | Myeloproliferative Disorders | Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease

Chronic Graft-Versus-Host-Disease

United States
Massachusetts General Hospital
Seagen Inc.

Terminated

Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)

GVHD | Graft-vs-Host Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
Masonic Cancer Center, University of Minnesota

Terminated

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Secondary Myelofibrosis

United States
Masonic Cancer Center, University of Minnesota

Terminated

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Terminated

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Fanconi Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Diamond-blackfan Anemia

United States
Mallinckrodt

Completed

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

Graft-versus-Host Disease

United States, Australia, France, Italy, Austria, Germany, Portugal, Slovakia, Spain, Switzerland, Turkey, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease

Graft vs Host Disease

United States
Massachusetts General Hospital

Completed

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institute of Allergy and Infectious...

Terminated

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myeloma | Graft Versus Host Disease

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Hospital Israelita Albert Einstein

Terminated

Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis (CICLODECH)

Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Acute Lymphoid Leukemia | Myeloproliferative Disease

Brazil

Search clinical trials for: Chronic Graft-versus-Host Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations